This research led to a recent discovery of a potent REV1-REV7 interface inhibitor, JH-RE-06, which exhibited TLS inhibition and significant synergy with cisplatin in human fibrosarcoma, melanoma and prostate adenocarcinoma cells [12]. Here, REV1 is linked to fibrosarcoma.